Adrenomedullin (ADM) has been shown to play a significant role in many physiological processes, including cellular growth, development, chemotaxis and migration Ref-1-6. It also has potent anti-microbial activity, eliciting its response through membrane channel formation and lysis, as well as anti-apoptotic actions Ref-7-10. However, two main actions are of significant interest in many disease conditions.

Microcirculation and vascular endothelial barrier function properties

Increasing evidence suggests that adrenomedullin may play a key role in reducing vascular permeability and increasing the stability of the microcirculation. Recent studies have shown that ADM may be involved in predicting sodium and extracellular fluid overload Ref-11 and plasma leakage Ref-12, reducing vascular hyperpermeability Ref-13, stabilising endothelial barrier fuction Ref-14, and redistributing blood flow back to sites which had experienced a lack of perfusion due to alpha-toxin infusion. Ref-15

In short: Adrenomedullin can accurately reflect the developing pathophysiological changes occurring in the microcirculation and microvascular during diseased conditions. Monitoring ADM levels, therefore, could be useful in evaluating disease progression or assessing the efficacy of therapeutic interventions on the host response.

adrenomedullin disease development

Adrenomedullin: a key role in disease development

  • Early predictor of organ dysfunction and outcome Ref-16
  • Protects against endothelial permeability and organ damage Ref-13,17,18
  • Protective effects in organs in response to bacterial induced shock Ref-19,20
  • Stabilization of microcirculation in inflammation Ref-15
  • Restoration of endothelial stability in infected organs Ref-21

Vasodilatory properties

Perhaps one of the most well known features of adrenomedullin are its vasodilatory properties. Increased circulating concentrations have been shown to result in a potent and sustained hypotension, mainly due to the generation of Nitric Oxide in the vasculature, with transient concentration surges contributing to the dramatic hypotension and vascular collapse found in patients with acute episodes of systemic capillary leak syndrome Ref-22. Acute or chronic increases in ADM can also result in a significant decrease in total peripheral resistance, a fall in blood pressure, and an increased heart rate, cardiac output and stroke volume.

Increases or decreases in adrenomedullin levels, therefore, can have a significant effect on blood supply to organs in certain disease settings.

adrenomedullin vasodilation

Adrenomedullin: vasodilation is key

  • Key mediator of vascular tone regulation resulting in an intense, prolonged vasorelaxation and hypotension Ref-23-28
  • Widespread production helps maintain blood supply to individual organs Ref-23,25,29
  • Localized cellular production to meet specific perfusion requirements of individual organs Ref-30,31
  • Significant role in hemorrhagic and endotoxic shock Ref-32-34, pulmonary hypertension Ref-35, hypertrophy Ref-36,37, hypoxia Ref-38-43, oxidative stress Ref-44, ischaemic myocardial injury Ref-45-48 and ischaemic injury and organ failure Ref-49,50

The dual actions of a double edged sword

Adrenomedullin is differentially increased in many diseased states, such as heart failure, sepsis, hypertension, and cardiovascular disease. Understanding and distinguishing between the dual actions of ADM is crucial in developing targeted treatment strategies. Significantly decreasing levels of ADM may result in a decrease in hypotension, yet simultaneously jeopardize vascular integrity Ref-22. Hence treatment should be targeted at decreasing or maintaining concentrations at a level which benefits both mechanistic properties.

References Adrenomedullin: mechanism of action

Ref-1: Kohno M, Yokokawa K, Kano H, et al. Adrenomedullin is a potent inhibitor of angiotensin II-induced migration of human coronary artery smooth muscle cells. Hypertension. 1997;29(6):1309-1313.

Ref-2: Fernandez S, Knopf MA, McGillis JP. Calcitonin-gene related peptide (CGRP) inhibits interleukin-7-induced pre-B cell colony formation. J Leukoc Biol. 2000;67(5):669-676.

Ref-3: Kamoi H, Kanazawa H, Hirata K, Kurihara N, Yano Y, Otani S. Adrenomedullin inhibits the secretion of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, from rat alveolar macrophages. Biochem Biophys Res Commun. 1995;211(3):1031-1035.

Ref-4: Kohno M, Yokokawa K, Yasunari K, et al. Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation. 1998;98(4):353-359.

Ref-5: Iwasaki H, Eguchi S, Shichiri M, Marumo F, Hirata Y. Adrenomedullin as a novel growth-promoting factor for cultured vascular smooth muscle cells: role of tyrosine kinase-mediated mitogen-activated protein kinase activation. Endocrinology. 1998;139(8):3432-3441.

Ref-6: Withers DJ, Coppock HA, Seufferlein T, Smith DM, Bloom SR, Rozengurt E. Adrenomedullin stimulates DNA synthesis and cell proliferation via elevation of cAMP in Swiss 3T3 cells. FEBS Lett. 1996;378(1):83-87.

Ref-7: Allaker RP, Zihni C, Kapas S. An investigation into the antimicrobial effects of adrenomedullin on members of the skin, oral, respiratory tract and gut microflora. FEMS Immunol Med Microbiol. 1999;23(4):289-293.

Ref-8: Yin H, Chao L, Chao J. Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling. Hypertension. 2004;43(1):109-116.

Ref-9: Allaker RP, Grosvenor PW, McAnerney DC, et al. Mechanisms of adrenomedullin antimicrobial action. Peptides. 2006;27(4):661-666.

Ref-10: Marutsuka K, Nawa Y, Asada Y, et al. Adrenomedullin and proadrenomudullin N-terminal 20 peptide (PAMP) are present in human colonic epithelia and exert an antimicrobial effect. Exp Physiol. 2001;86(5):543-545.

Ref-11: Vigue B, Leblanc PE, Moati F, et al. Mid-regional pro-adrenomedullin (MR-proADM), a marker of positive fluid balance in critically ill patients: results of the ENVOL study. Crit Care. 2016;20(1):363.

Ref-12: Michels M, Djamiatun K, Faradz SM, Koenders MM, de Mast Q, van der Ven AJ. High plasma mid-regional pro-adrenomedullin levels in children with severe dengue virus infections. J Clin Virol. 2011;50(1):8-12.

Ref-13: Temmesfeld-Wollbruck B, Brell B, David I, et al. Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock. Intensive Care Med. 2007;33(4):703-710.

Ref-14: Temmesfeld-Wollbruck B, Hocke AC, Suttorp N, Hippenstiel S. Adrenomedullin and endothelial barrier function. Thromb Haemost. 2007;98(5):944-951.

Ref-15: Brell B, Hippenstiel S, David I, et al. Adrenomedullin treatment abolishes ileal mucosal hypoperfusion induced by Staphylococcus aureus alpha-toxin--an intravital microscopic study on an isolated rat ileum. Crit Care Med. 2005;33(12):2810-2016.

Ref-16: Ueda S, Nishio K, Minamino N, et al. Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. Am J Respir Crit Care Med. 1999;160(1):132-136.

Ref-17: Muller-Redetzky HC, Will D, Hellwig K, et al. Mechanical ventilation drives pneumococcal pneumonia into lung injury and sepsis in mice: protection by adrenomedullin. Crit Care. 2014;18(2):R73.

Ref-18: Vallet B. Endothelial cell dysfunction and abnormal tissue perfusion. Crit Care Med. 2002;30(5 Suppl):S229-234.

Ref-19: Gonzalez-Rey E, Chorny A, Varela N, Robledo G, Delgado M. Urocortin and adrenomedullin prevent lethal endotoxemia by down-regulating the inflammatory response. Am J Pathol. 2006;168(6):1921-1930.

Ref-20: Carrizo GJ, Wu R, Cui X, Dwivedi AJ, Simms HH, Wang P. Adrenomedullin and adrenomedullin-binding protein-1 downregulate inflammatory cytokines and attenuate tissue injury after gut ischemia-reperfusion. Surgery. 2007;141(2):245-253.

Ref-21: Pugin J. Adrenomedullin: a vasodilator to treat sepsis? Crit Care. 2014;18(3):152.

Ref-22: Xie Z, Chen WS, Yin Y, et al. Adrenomedullin surges are linked to acute episodes of the systemic capillary leak syndrome (Clarkson disease). J Leukoc Biol. 2018.

Ref-23: Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993;192(2):553-560.

Ref-24: Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Muller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care. 2005;9(6):R816-824.

Ref-25: Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000;21(2):138-167.

Ref-26: Landry DW, Oliver JA. Insights into shock. Sci Am. 2004;290(2):36-41.

Ref-27: Ishiyama Y, Kitamura K, Ichiki Y, et al. Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. Eur J Pharmacol. 1993;241(2-3):271-273.

Ref-28: Ishiyama Y, Kitamura K, Ichiki Y, et al. Haemodynamic responses to rat adrenomedullin in anaesthetized spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1995;22(9):614-618.

Ref-29: Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides. 2001;22(11):1693-1711.

Ref-30: Elsasser TH, Kahl S. Adrenomedullin has multiple roles in disease stress: development and remission of the inflammatory response. Microsc Res Tech. 2002;57(2):120-129.

Ref-31: Takahashi K, Nakayama M, Totsune K, et al. Increased secretion of adrenomedullin from cultured human astrocytes by cytokines. J Neurochem. 2000;74(1):99-103.

Ref-32: Fujioka S, Ono Y, Kangawa K, Okada K. Plasma concentration of adrenomedullin is increased in hemorrhagic shock in dogs. Anesth Analg. 1999;88(2):326-328.

Ref-33: Kikumoto K, Kubo A, Hayashi Y, et al. Increased plasma concentration of adrenomedullin in patients with subarachnoid hemorrhage. Anesth Analg. 1998;87(4):859-863.

Ref-34: Ono Y, Kojima M, Okada K, Kangawa K. cDNA cloning of canine adrenomedullin and its gene expression in the heart and blood vessels in endotoxin shock. Shock. 1998;10(4):243-247.

Ref-35: Kakishita M, Nishikimi T, Okano Y, et al. Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin Sci (Lond). 1999;96(1):33-39.

Ref-36: Tsuruda T, Kato J, Kitamura K, et al. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension. 1998;31(1 Pt 2):505-510.

Ref-37: Yoshihara F, Nishikimi T, Horio T, et al. Chronic infusion of adrenomedullin reduces pulmonary hypertension and lessens right ventricular hypertrophy in rats administered monocrotaline. Eur J Pharmacol. 1998;355(1):33-39.

Ref-38: Cormier-Regard S, Nguyen SV, Claycomb WC. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J Biol Chem. 1998;273(28):17787-17792.

Ref-39: Cejudo-Martin P, Morales-Ruiz M, Ros J, et al. Hypoxia is an inducer of vasodilator agents in peritoneal macrophages of cirrhotic patients. Hepatology. 2002;36(5):1172-1179.

Ref-40: Nagata D, Hirata Y, Suzuki E, et al. Hypoxia-induced adrenomedullin production in the kidney. Kidney Int. 1999;55(4):1259-1267.

Ref-41: Trollmann R, Schoof E, Beinder E, Wenzel D, Rascher W, Dotsch J. Adrenomedullin gene expression in human placental tIssue and leukocytes: a potential marker of severe tIssue hypoxia in neonates with birth asphyxia. Eur J Endocrinol. 2002;147(5):711-716.

Ref-42: Hofbauer KH, Jensen BL, Kurtz A, Sandner P. Tissue hypoxygenation activates the adrenomedullin system in vivo. Am J Physiol Regul Integr Comp Physiol. 2000;278(2):R513-519.

Ref-43: Nakayama M, Takahashi K, Murakami O, Shirato K, Shibahara S. Induction of adrenomedullin by hypoxia in cultured human coronary artery endothelial cells. Peptides. 1999;20(6):769-772. 44. Ando K, Ito Y, Kumada M, Fujita T. Oxidative stress increases adrenomedullin mRNA levels in cultured rat vascular smooth muscle cells. Hypertens Res. 1998;21(3):187-191.

Ref-45: Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353(13):1332-1341.

Ref-46: Nagaya N, Nishikimi T, Uematsu M, et al. Plasma adrenomedullin as an indicator of prognosis after acute myocardial infarction. Heart. 1999;81(5):483-487.

Ref-47: Oie E, Vinge LE, Yndestad A, Sandberg C, Grogaard HK, Attramadal H. Induction of a myocardial adrenomedullin signaling system during ischemic heart failure in rats. Circulation. 2000;101(4):415-422.

Ref-48: Vijay P, Szekely L, Aufiero TX, Sharp TG. Coronary sinus adrenomedullin rises in response to myocardial injury. Clin Sci (Lond). 1999;96(4):415-420.

Ref-49: Ishimitsu T, Nishikimi T, Saito Y, et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest. 1994;94(5):2158-2161.

Ref-50: Wang X, Yue TL, Barone FC, et al. Discovery of adrenomedullin in rat ischemic cortex and evidence for its role in exacerbating focal brain ischemic damage. Proc Natl Acad Sci U S A. 1995;92(25):11480-11484.